Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 induction and maintenance study in moderate-to-severe Crohn's disease
NL-OMON44996Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in Crohn's disease (11 arms), sponsored by AbbVie Inc. Primary endpoints: Endoscopic remission at Week 12/16 and Clinical remission at Week 16. Started Jan 2016; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON44996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44996.